Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22091411 | 0.73 | ALDH1A1 (0.45) | BRD4SMN1; SMN2CYP11B2HDAC1HDAC6 | |
| SCHEMBL22091425 | 0.73 | ALDH1A1 (0.45) | BRD4SMN1; SMN2CYP11B2HDAC1HDAC6 | |
| SCHEMBL24754233 | 0.73 | BRD4 (0.42) | BRD4SMN1; SMN2CYP11B2GAAHDAC1 | |
| SCHEMBL24754395 | 0.73 | BRD4 (0.42) | BRD4SMN1; SMN2CYP11B2GAAHDAC1 | |
| SCHEMBL24754376 | 0.72 | BRD4 (0.41) | BRD4SMN1; SMN2CYP11B2MAPK14HDAC1 | |
| SCHEMBL24754388 | 0.70 | MAPK14 (0.39) | BRD4RECQLSMN1; SMN2MAPK14GAA | |
| SCHEMBL23516966 | 0.70 | ALDH1A1 (0.50) | BRD4SMN1; SMN2HDAC1HDAC6EGLN1 | |
| SCHEMBL24754375 | 0.70 | ALDH1A1 (0.44) | BRD4SMN1; SMN2HDAC1HDAC6KMT2A | |
| SCHEMBL24754230 | 0.69 | TBXAS1 (0.43) | BRD4SMN1; SMN2HDAC1HDAC6KMT2A | |
| SCHEMBL29932365 | 0.68 | SMN1; SMN2 (0.63) | RECQLMAPK10SMN1; SMN2GAAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115003658-B | Compounds and their use for the treatment of alpha1Use of antitrypsin deficiency | 森特萨制药(英国)有限公司 | 2024-07-23 | — | — | CN | claimed |
| EP-4073043-B1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | CENTESSA PHARMACEUTICALS UK LTD (GB) | 2024-04-03 | — | — | EP | claimed |
| CN-115003658-B | Compounds and their use for the treatment of alpha1Use of antitrypsin deficiency | 森特萨制药(英国)有限公司 | 2024-07-23 | — | — | CN | disclosed |
| US-20230102488-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | OXFORD FINANCE LLC | 2023-03-30 | — | — | US | disclosed |
| WO-2022263829-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-12-22 | — | — | WO | disclosed |
| EP-4073043-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230102488-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | SERPINA2, SERPINB1, SERPINH1 | BRD4 1386/4885RECQL 1765/4885MAPK10 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.